2023-508126-95-00
Recruiting
Phase 1
A Phase 1 Prospective, Open-label, First-in-human Study to Evaluate the Safety, Tolerability and Biodistribution of [177Lu]Lu-AKIR001 and its Anti-tumour Effect in Adult Patients with CD44v6 Expressing Solid Tumours
Karolinska University Hospital1 site in 1 country30 target enrollmentSeptember 12, 2024
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Karolinska University Hospital
- Enrollment
- 30
- Locations
- 1
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Robert Bränström
Scientific
Karolinska University Hospital
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Phase 1
First in human clinical trial to evaluate the safety, tolerability and preliminary efficacy of the bispecific CD276xCD3 antibody CC-3 in patients with colorectal cancer2022-503084-15-00Deutsches Krebsforschungszentrum (DKFZ)77
Recruiting
Phase 1
Phase 1 First-In-Human Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors2022-502867-39-00Amgen Inc.58
Recruiting
Not Applicable
A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid TumorsjRCT2031230002Astrazeneca K.K417
Recruiting
Not Applicable
A Phase I, first-in-human, multicenter, open-label, dose escalation followed by an expansion phase clinical study of KBA1412 given as monotherapy or in combination with pembrolizumab in adults with advanced solid malignant tumorsmelanomaSolid Tumors10018865NL-OMON53468Kling Biotherapeutics B.V.22
Suspended
Phase 2
ECUR-506 in Neonatal OTC Deficiency Phase I/IIOrnithine Transcarbamylase (OTC) DeficiencyGenetic DiseasesISRCTN10957794Fortrea Development Ltd13